In this online, self-learning activity:
The incidence of differentiated thyroid cancer (DTC) has risen over the last decade, and there are over 43,000 new cases and 2,200 deaths each year. DTC accounts for 95% of all thyroid cancers and can be categorized as papillary or follicular cancer. Thyroid cancer diagnosed and treated at an early stage has a favorable prognosis, with a 5-year survival rate of 99.9%. However, 5-year survival decreases to 53.3% for those patients with advanced or metastatic disease. Patients with disease that has progressed despite TSH-suppressive therapy or radioiodine may be considered for systemic therapy. Patients without a specific targetable marker may receive a multitargeted kinase inhibitor, while those with one may preferentially receive another agent such as a RET inhibitor, NTRK inhibitor, or BRAF inhibitor. DTC may present with actionable mutations, so patients with radioiodine-refractory (RAI-R) or metastatic disease should undergo genomic testing to assess mutation status, deficient mismatch repair (dMMR), microsatellite instability (MSI), and tumor mutational burden (TMB) to identify therapeutic targets.
HCPs including: Medical oncologists and endocrinologists; physician assistants, nurse practitioners, nurses, and pharmacists who practice in oncology; and any other healthcare professionals with an interest in or who clinically encounter patients with RAI-R or metastatic DTC.
Commercial Support Disclosure: This program is supported by an educational grant from Exelixis.
This activity is free of charge.
Release Date: May 11, 2023 -- Expiration Date: May 11, 2024
Faculty: Gregory Daniels, MD, PhD
Faculty introduction, disclosures |
Introductory content: defining the context and challenge of RAI-R and metastatic DTC
|
Treatment of DTC
|
Summary, conclusions, and best practice recap |
By the end of the session the participant will be able to:
ACCME Activity #202515817
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through ScientiaCME. ScientiaCME is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation: ScientiaCME designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ toward the AMA Physician's Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.
ABIM MOC Recognition Statement: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
ABIM MOC Credit Type: Medical Knowledge
Physicians: For maintenance of certification (MOC) points, you must enter your board certification ID # and birth date correctly. It is the learner's responsibility to provide this information completely and accurately at the completion of the activity. Without providing it, the learner will NOT receive MOC points for this activity. By providing this data, you acknowledge that it will be shared with ACCME and the applicable certifying board. Please note: Not all activities on this site provide MOC points. If this activity does not specify that it provides MOC points in this section, then it does NOT provide MOC points. This activity provides MOC points only for ABIM.
Pharmacists
ScientiaCME is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.1 CEUs) of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit. ACPE #0574-0000-23-018-H01-P. This is an Knowledge (K)-type activity.
Pharmacists: You must enter your NABP # and birth date correctly so that proof of participation can be posted to your NABP CPE profile. It is the learner's responsibility to provide this information completely and accurately at the completion of the activity. Without providing it, the learner will NOT receive CPE credit for this activity.
Nurse Practitioners (NPs): The American Academy of Nurse Practitioners accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. ScientiaCME will provide NPs who successfully complete each activity with a certificate of participation indicating that the activity was designated for AMA PRA Category 1 Credit(s)™.
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.
Disclosure of Faculty: Gregory A. Daniels, MD, PhD, Professor of Medicine, University of California San Diego, has no relevant financial disclosures.
Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.
Faculty WILL discuss off-label uses.
All relevant financial relationships have been mitigated.
ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Commercial Support Disclosure: This program is supported by an educational grant from Exelixis.
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Contemporary treatment approaches in the management of graft-versus-host disease (GVHD)
Myeloma bone disease: Monitoring and management
Preventing and mitigating skeletal-related events in breast cancer
Prediction and management of bone complications in prostate cancer